Bevacizumab
Medication
Ratings
0
Nobody has rated this yet. Be the first!
Subject of
14
Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies
Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Improved survival with bevacizumab in advanced cervical cancer
Optic neuropathy in patients with glioblastoma receiving bevacizumab
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Bevacizumab: optimal dose, schedule, and duration of therapy.
A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
